Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate
Ang Jia1, Xiaowen Zhang2, Ji-Hao Zhou3
1Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Drug Clinical Trial Center, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Institute of Clinical Mass Spectrometry, Shanghai Academy of Experimental Medicine, Shanghai, China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Abstract:
Acute myeloid leukemia (AML) arises from diverse mutations, yet its most aggressive drivers remain elusive. Here, we show that Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations drive hyperproliferative and therapy-/glucose stress-resistant AML, whereas existing inhibitors lack sufficient cytotoxicity. Dual physiological/glucose-deprived screening identified compound 615 selectively eliminating KRAS-mutant cells through concurrently inhibiting succinate dehydrogenase (SDH) and the cytosol-to-mitochondrial NAD+ transporter SLC25A51. Mechanistically, KRAS-mutant cells exhibit reduced 2-oxoglutarate dehydrogenase complex-mediated SLC25A51 K264 succinylation, a mitochondrial NAD+-dependent modification promoting protein stability. This creates a synthetic lethal vulnerability: low-dose 615 triggers a cascade failure by acutely inhibiting SLC25A51, followed by its destabilization, causing complete transporter suppression. Together with concurrent SDH inhibition, this drives catastrophic mitochondrial NAD+ depletion. Conversely, KRAS-wild-type cells preserve NAD+ influx via sufficient baseline succinyl-SLC25A51, which stabilizes SLC25A51 and enables sufficient succinate accumulation to drive hypoxia inducible factor 1 subunit alpha (HIF1α)-mediated compensatory NAD+ production during treatment. Our work reveals a KRAS-specific metabolic vulnerability and proposes a dual-inhibition therapy for KRAS-driven AML.
Insights
New research identifies Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations as key drivers of aggressive Acute Myeloid Leukemia (AML). A novel dual-targeting compound selectively eliminates KRAS-mutant AML cells by disrupting mitochondrial NAD+ metabolism.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Pathways
Background:
- Acute Myeloid Leukemia (AML) heterogeneity complicates treatment, with aggressive drivers often remaining unidentified.
- Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are implicated in hyperproliferative and therapy-resistant AML, but current inhibitors show limited efficacy.
Purpose of the Study:
- To identify novel therapeutic targets and strategies for KRAS-mutant AML.
- To investigate the metabolic vulnerabilities associated with KRAS-driven AML.
Main Methods:
- Utilized dual physiological/glucose-deprived screening to identify selective cytotoxic compounds.
- Investigated the mechanism of action of compound 615, focusing on succinate dehydrogenase (SDH) and SLC25A51 inhibition.
- Analyzed mitochondrial NAD+ metabolism and protein succinylation in KRAS-mutant versus wild-type AML cells.
Main Results:
- Compound 615 selectively eliminates KRAS-mutant AML cells by inhibiting both SDH and the mitochondrial NAD+ transporter SLC25A51.
- KRAS-mutant cells exhibit reduced SLC25A51 succinylation, creating a synthetic lethal vulnerability exploited by compound 615.
- Dual inhibition leads to catastrophic mitochondrial NAD+ depletion in KRAS-mutant cells, while KRAS-wild-type cells maintain NAD+ homeostasis.
Conclusions:
- KRAS mutations confer a specific metabolic vulnerability in AML related to mitochondrial NAD+ transport.
- Compound 615 represents a promising dual-inhibition therapeutic strategy for KRAS-driven AML.
- Understanding KRAS-specific metabolic dependencies opens new avenues for targeted AML therapies.
More Related Videos
Related Concept Videos
Animal Mitochondrial Genetics
Export of Mitochondrial and Chloroplast Genes
The Citric Acid Cycle
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
MOSFET: Depletion Mode
The primary characteristic of depletion-mode MOSFETs is their ability to conduct current between the drain and source terminals without gate bias. This inherent conductivity...
What is Natural Selection?


